Caffeine use in preterm neonates: national insights into Turkish NICU practices.

IF 2.1 3区医学 Q2 PEDIATRICS

Frontiers in Pediatrics Pub Date : 2025-02-27 eCollection Date: 2025-01-01 DOI:10.3389/fped.2025.1492716

Sezin Unal, Serdar Beken, Deniz Anuk Ince, Ozden Turan, Ayse Korkmaz Toygar, Ayse Ecevit, Abdullah Baris Akcan, Mustafa Ali Akın, Selma Aktas, Nukhet Aladag Ciftdemir, Emel Altuncu, Huseyin Altunhan, Baran Cengiz Arcagok, Didem Armangil, Esra Arun Ozer, Banu Aydın, Handan Bezirganoglu, Leyla Bilgin, Erhan Calısıcı, Sebnem Calkavur, Kıymet Celik, Yalcın Celik, Bilin Cetinkaya, Merih Cetinkaya, Atalay Demirel, Gamze Demirel, Nazan Neslihan Dogan, Pelin Doğan, Mehtap Durukan, Defne Engur, Tugba Erener Ercan, Zeynel Gokmen, Ipek Guney Varal, Selvi Gulası, Ayla Gunlemez, Tugba Gursoy, Handan Hakyemez Toptan, Serif Hamitoğlu, Fatih Isleyen, Irem Iyigun, Sebnem Kader, Dilek Kahvecioğlu, Gozdem Kaykı, Murat Kostu, Dilek Kurnaz, Tural Mammadalıyev, Ilke Mungan Akin, Nejat Narlı, Emel Okulu, Nilufer Okur, Ozgur Olukman, Fahri Ovalı, Beyza Ozcan, Ahmet Ozdemir, Ozmert Ozdemir, Hilal Ozkan, Gonca Sandal, Dilek Sarıcı, Cansu Sivrikaya, Betul Siyah Bilgin, Saime Sundus, Ozge Surmeli Onay, Huseyin Simsek, Umit Ayse Tandırcıoğlu, Sema Tanrıverdi, Kadir Serafettin Tekgunduz, Demet Terek, Gaffari Tunc, Turan Tunc, Ercan Tutak, Eda Tufekcioğlu, Funda Tuzun Erdogan, Ersin Ulu, Dilek Ulubas Isik, Nurdan Uras, Sait Ilker Uslu, Irem Unal, Fatma Hilal Yılmaz, Ariorad Moniri

{"title":"Caffeine use in preterm neonates: national insights into Turkish NICU practices.","authors":"Sezin Unal, Serdar Beken, Deniz Anuk Ince, Ozden Turan, Ayse Korkmaz Toygar, Ayse Ecevit, Abdullah Baris Akcan, Mustafa Ali Akın, Selma Aktas, Nukhet Aladag Ciftdemir, Emel Altuncu, Huseyin Altunhan, Baran Cengiz Arcagok, Didem Armangil, Esra Arun Ozer, Banu Aydın, Handan Bezirganoglu, Leyla Bilgin, Erhan Calısıcı, Sebnem Calkavur, Kıymet Celik, Yalcın Celik, Bilin Cetinkaya, Merih Cetinkaya, Atalay Demirel, Gamze Demirel, Nazan Neslihan Dogan, Pelin Doğan, Mehtap Durukan, Defne Engur, Tugba Erener Ercan, Zeynel Gokmen, Ipek Guney Varal, Selvi Gulası, Ayla Gunlemez, Tugba Gursoy, Handan Hakyemez Toptan, Serif Hamitoğlu, Fatih Isleyen, Irem Iyigun, Sebnem Kader, Dilek Kahvecioğlu, Gozdem Kaykı, Murat Kostu, Dilek Kurnaz, Tural Mammadalıyev, Ilke Mungan Akin, Nejat Narlı, Emel Okulu, Nilufer Okur, Ozgur Olukman, Fahri Ovalı, Beyza Ozcan, Ahmet Ozdemir, Ozmert Ozdemir, Hilal Ozkan, Gonca Sandal, Dilek Sarıcı, Cansu Sivrikaya, Betul Siyah Bilgin, Saime Sundus, Ozge Surmeli Onay, Huseyin Simsek, Umit Ayse Tandırcıoğlu, Sema Tanrıverdi, Kadir Serafettin Tekgunduz, Demet Terek, Gaffari Tunc, Turan Tunc, Ercan Tutak, Eda Tufekcioğlu, Funda Tuzun Erdogan, Ersin Ulu, Dilek Ulubas Isik, Nurdan Uras, Sait Ilker Uslu, Irem Unal, Fatma Hilal Yılmaz, Ariorad Moniri","doi":"10.3389/fped.2025.1492716","DOIUrl":null,"url":null,"abstract":"Objective: Caffeine is a proven medication used for the prevention and treatment of apnea in premature infants, offering both short- and long-term benefits. International guidelines provide a range of recommendations regarding the preterm population eligible for caffeine prophylaxis, including the timing, dosage, and duration of treatment. Our national guidelines, published prior to the most recent updates of the international guidelines, recommend the use of caffeine citrate starting from the first day after delivery for preterm infants with a gestational age of <28 weeks. For infants up to 32 weeks, if positive pressure ventilation is required, the decision should be made on an individual basis. This study aims to describe the variability in caffeine usage across neonatal intensive care units in our country.Methods: An online survey was sent to neonatologist who are members of the Turkish Neonatology Society to describe the variability in caffeine usage in neonatal intensive care units in our country.Results: We collected responses from 74 units. Prophylactic caffeine usage was observed as; GA ≤276/7: 98.6%, GA 280/7-286/7: 89.0%, GA 290/7-296/7: 75.3%, GA 300/7-316/7: 53.4%. 62.2% of units reported administering loading dose within the first two hours. The initial maintenance dose was 5 mg/kg in 64.8% of units, 10 mg/kg in 32.4% of units, and intermediate dose in 5.3% of units. 47.3% of units reported no routine dose adjustment. The postmenstrual age that caffeine treatment was stopped was found to be 34 (min-max; 32-36) weeks for infants without apnea and respiratory support, 36 (min-max; 34-52) weeks for infants without apnea but any respiratory support. The time to discharge after treatment cessation was found as; 1-4 days: 37.8%, 5-7 days: 68.9%. Among the 56 units with multiple responsible physicians, 32.1% reported intra-unit variations.Conclusion: The significant differences in caffeine usage characteristics between and within units highlight the need for clear recommendations provided by standardized guidelines.","PeriodicalId":12637,"journal":{"name":"Frontiers in Pediatrics","volume":"13 ","pages":"1492716"},"PeriodicalIF":2.1000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11905296/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fped.2025.1492716","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Caffeine is a proven medication used for the prevention and treatment of apnea in premature infants, offering both short- and long-term benefits. International guidelines provide a range of recommendations regarding the preterm population eligible for caffeine prophylaxis, including the timing, dosage, and duration of treatment. Our national guidelines, published prior to the most recent updates of the international guidelines, recommend the use of caffeine citrate starting from the first day after delivery for preterm infants with a gestational age of <28 weeks. For infants up to 32 weeks, if positive pressure ventilation is required, the decision should be made on an individual basis. This study aims to describe the variability in caffeine usage across neonatal intensive care units in our country.

Methods: An online survey was sent to neonatologist who are members of the Turkish Neonatology Society to describe the variability in caffeine usage in neonatal intensive care units in our country.

Results: We collected responses from 74 units. Prophylactic caffeine usage was observed as; GA ≤27^6/7: 98.6%, GA 28^0/7-28^6/7: 89.0%, GA 29^0/7-29^6/7: 75.3%, GA 30^0/7-31^6/7: 53.4%. 62.2% of units reported administering loading dose within the first two hours. The initial maintenance dose was 5 mg/kg in 64.8% of units, 10 mg/kg in 32.4% of units, and intermediate dose in 5.3% of units. 47.3% of units reported no routine dose adjustment. The postmenstrual age that caffeine treatment was stopped was found to be 34 (min-max; 32-36) weeks for infants without apnea and respiratory support, 36 (min-max; 34-52) weeks for infants without apnea but any respiratory support. The time to discharge after treatment cessation was found as; 1-4 days: 37.8%, 5-7 days: 68.9%. Among the 56 units with multiple responsible physicians, 32.1% reported intra-unit variations.

Conclusion: The significant differences in caffeine usage characteristics between and within units highlight the need for clear recommendations provided by standardized guidelines.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Pediatrics Medicine-Pediatrics, Perinatology and Child Health

CiteScore

3.60

自引率

7.70%

发文量

2132

审稿时长

14 weeks

期刊介绍： Frontiers in Pediatrics (Impact Factor 2.33) publishes rigorously peer-reviewed research broadly across the field, from basic to clinical research that meets ongoing challenges in pediatric patient care and child health. Field Chief Editors Arjan Te Pas at Leiden University and Michael L. Moritz at the Children''s Hospital of Pittsburgh are supported by an outstanding Editorial Board of international experts. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. Frontiers in Pediatrics also features Research Topics, Frontiers special theme-focused issues managed by Guest Associate Editors, addressing important areas in pediatrics. In this fashion, Frontiers serves as an outlet to publish the broadest aspects of pediatrics in both basic and clinical research, including high-quality reviews, case reports, editorials and commentaries related to all aspects of pediatrics.